演題抄録

International Session(Poster)

開催概要
開催回
第51回・2013年・京都
 

Results of chemotherapy in the patients with metastatic or recurrent HNSCC

演題番号 : ISP-6

[筆頭演者]
Hunho Song:1 
[共同演者]
Hyo Jung Kim:2、Geundoo Jang:1、Jung Hye Kwon:1、Boram Han:2、Jung Han Kim:4、Hyeong Su Kim:4、Dae Ro Choi:3

1:Internal Medicine/Hemato-oncology, Kangdong Sacred Heart Hospital, College of Medicine, Hallym Univ., Korea、2:Internal Medicine/Hemato-oncology, Hallym Sacred Heart Hospital, College of Medicine, Hallym Univ., Korea、3:Internal Medicine, Chuncheon Sacred Heart Hospital, College of Medicine, Hallym Univ., Korea、4:Internal Medicine/Hemato-oncology, Kangnam Sacred Heart Hospital, College of Medicine, Hallym Univ., Korea

 

Purpose: Prognosis of metastatic or recurrent head and neck squamous cell carcinoma (R/M HNSCC) is very poor. In this retrospective analysis, we examined the effect of chemotherapy on patients (pts.) with R/M HNSCC. We also analyzed the prognostic factors affecting the response rate and survival. Methods: We retrospectively analyzed the clinical records of the pts. with R/M HNSCC who received systemic chemotherapy at the Hallym University Medical Center between January 2006 and December 2012. The 47 pts. enrolled were categorized into 2 groups according to time of relapse: those who had recurrent HNSCC within 3 months (mo.) following prior curative therapy (group A) and those who did not (group B). Results: Of the 47 pts., 41 had recurrent disease. The chemotherapy regimens were as follows: 17 pts. received combination chemotherapy with 5-FU and cisplatin; 9 received S-1 and cisplatin; 10 received docetaxel and cisplatin; 7 received docetaxel, 5-FU and cisplatin; and 4 received cetuximab-containing regimen. The median number of chemotherapy cycles was 3 (range, 1-6 cycles). The overall response rate was 29.8% and the disease control rate was 53.2%. PFS was 3.7 mo. (95% confidence interval [CI], 2.7_4.7 mo.) and OS was 6.4 mo. (95% CI, 5.1_7.7). In univariated analysis, group B, serum albumin level (>4.0 g/dL), hemoglobin (>11.0 g/dL) were associated with longer PFS significantly. Group B, performance status, response rate, disease control rate, distant metastasis at the diagnosis were associated with a better OS. OS was 5.7 mo. and 7.1 mo. for groups A and B respectively (p=0.018). Seven pts. who were alive more than 15 mo. belonged to group B. This might be the key to predicting prognosis before the start of chemotherapy.Conclusion: The outcomes of systemic chemotherapy in pts. with R/M HNSCC were poor, especially in pts. who showed recurrence within 3 mo. following curative treatment. New prognostic factors must be identified for proper management of HNSCC pts.

前へ戻る